Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 7,709 | 427 | 7,191 |
| Samples | 4,128 | 294 | 3,786 |
| Peptides | 541 | 81 | 499 |
Function
PIK3CA · Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers. A pseudogene of this gene has been defined on chromosome 22. [provided by RefSeq, Apr 2016].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000263967 | P42336 | 4,592 | 533 |
| ENST00000643187 | A0A2R8Y2F6* | 3,117 | 445 |
Gene Properties
Recurrent Mutations
All 533 amino-acid changes on canonical ENST00000263967 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PIK3CA · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PIK3CA – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 22/42 52% | 280/612 46% |
| Breast Carcinoma | 43/144 30% | 1011/3264 31% |
| Cervical Carcinoma | 10/35 29% | 106/422 25% |
| Bladder Carcinoma | 19/58 33% | 204/956 21% |
| Colorectal Carcinoma | 44/143 31% | 600/3239 19% |
| Oral Cavity Carcinoma | 10/54 19% | 0/0 0% |
| Unknown | 0/10 0% | 7/29 24% |
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Gastric Carcinoma | 12/74 16% | 202/1809 11% |
| Head and Neck Carcinoma | 6/85 7% | 175/1574 11% |
| Squamous Cell Lung Carcinoma | 7/57 12% | 82/810 10% |
| Esophageal Squamous Cell Carcinoma | 4/51 8% | 222/2550 9% |
| Other Sarcomas | 6/69 9% | 60/699 9% |
| Glioblastoma | 8/98 8% | 0/0 0% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Ovarian Carcinoma | 26/109 24% | 60/998 6% |
| Esophageal Carcinoma | 4/23 17% | 55/769 7% |
| Glioma | 2/52 4% | 159/2127 7% |
| Non-Small Cell Lung Carcinoma | 21/304 7% | 80/1390 6% |
| Biliary Tract Carcinoma | 3/54 6% | 54/950 6% |
| Small Cell Lung Carcinoma | 0/9 0% | 38/752 5% |
| Rhabdomyosarcoma | 0/33 0% | 9/171 5% |
| Other Solid Cancers | 3/94 3% | 63/1515 4% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Medulloblastoma | 0/0 0% | 13/450 3% |
| Melanoma | 3/210 1% | 58/1899 3% |
| Neuroendocrine Tumour | 8/154 5% | 12/577 2% |
| Non-Cancerous | 0/104 0% | 25/830 3% |
| Pancreatic Carcinoma | 2/89 2% | 43/1611 3% |
| Prostate Carcinoma | 2/13 15% | 54/2105 3% |
Mutation Distribution
Where PIK3CA is mutated · all tissues, split by cell line vs tissue
How many mutations in PIK3CA were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 7,709 mutations in PIK3CA
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|